Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Treasury Shares (2016 - 2025)

Collegium Pharmaceutical (COLL) has 6 years of Treasury Shares data on record, last reported at $222.5 million in Q3 2025.

  • For Q3 2025, Treasury Shares rose 29.08% year-over-year to $222.5 million; the TTM value through Sep 2025 reached $222.5 million, up 29.08%, while the annual FY2024 figure was $197.5 million, 43.76% up from the prior year.
  • Treasury Shares reached $9.0 million in Q3 2025 per COLL's latest filing, up from $2.7 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $9.0 million in Q3 2025 and bottomed at -$859040.0 in Q3 2021.
  • Average Treasury Shares over 5 years is $3.6 million, with a median of $3.1 million recorded in 2023.
  • Peak YoY movement for Treasury Shares: soared 210.54% in 2022, then increased 29.08% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $42.9 million in 2021, then skyrocketed by 44.48% to $61.9 million in 2022, then soared by 121.85% to $137.4 million in 2023, then surged by 43.76% to $197.5 million in 2024, then rose by 12.66% to $222.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $222.5 million in Q3 2025, $217.5 million in Q2 2025, and $197.5 million in Q1 2025.